InhaltsangabeI. Trends in prostate cancer screening 1) Overview of US Prostate Cancer Trends in the Era of PSA Screening Ruth Etzioni, MD, Roman Gulati, Angela Mariotto, PhD. 2) Trends in Prostate Cancer Screening: Overview of the UK Freddie C Hamdy, MD, Richard J Bryant, MD 3) Trends in prostate cancer screening: Canada Robert K Nam, MD, Laurence H Klotz, MD 4) Trends in prostate cancer screening: Europe Sanjai Addla, FRCS, Robert Djavan, MD, PhD II. Prostate Specific Antigen 5) Evolution of Prostate Specific Antigen for screening Javier Hernandez, MD, MS, Edith Canby-Hagino, MD, MS 6) The performance characteristics of prostate specific antigen for prostate cancer screening Ian M. Thompson, MD, Donna P. Ankerst, PhD 7) The performance of PSA after a prior negative prostate biopsy Catherine M Tangen, Dr. PH 8) Subfractions and derivatives of total prostate specific antigen in the early detection of prostate cancer Alexander Haese, MD, PhD, Alan W Partin, MD, PhD 9) PSA velocity at presentation as a predictor of prostate cancer aggressiveness Jason A Efstathiou, MD, PhD, Anthony D'Amico, MD, PhD III. Risk assessment for prostate cancer 10) Nomograms for prostate cancer Shahrokh F Shariat, MD, Mike W Kattan, MD 11) Artificial neural networks for optimizing prostate cancer risk prediction Felix K.-H. Chun, MD, Pierre I. Karakiewicz, MD 12) Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator Donna P Ankerst, PhD, Ian M Thompson, MD 13) Integration of risk assessment in prostate cancer screening Kadee Thompson, MD, Amanda Reed, MD, Dipen J Parekh, MD 14) Family history ofprostate cancer during rapidly increasing incidence Kari Hemminki, MD, Justo Lorenzo Bermelo, MD IV. Recent biomarkers for prostate cancer 15) PSA Isoforms:[-2]proPSA Significant Adjunct to Free PSA Jeffrey E Tam 16) PCA3 Jack Groskopf, PhD, Jack Schalken, PhD, Harry Rittenhouse, PhD 17) Transcriptional profiling for prostate cancer biomarker identification and clinical applications Nigel Clegg, PhD, Peter S Nelson, MD 18) Biomarkers for prostate cancer detection: family-based linkage analysis and case-control association studies Joke Beuten, Teresa L Johnson-Pais. 19) GSTP1 hypermethylation for prostate cancer detection Rui Henrique, MD, PhD, Carmen Jeronimo, PhD 20) EPCA and EPCA-2 as potential biomarkers for prostate cancer detection Eddy S Leman, PhD, Robert H Getzenberg, PhD V. Design and methodologic considerations in biomarker studies 21) Towards a robust system for biomarker triage and validations-EDRN experience Ziding Feng, PhD 22) Statistical evaluation of markers and risk tools for prostate cancer classification and prediction Yingye Zheng, PhD, Donna P Ankerst, PhD 23) Pitfalls in prostate cancer biomarker evaluation studies Donna P Ankerst, PhD VI. Building upon recently completed and ongoing prospective trials 24) Prostate-specific antigen and its role on the Prostate Cancer Prevention Trial Catherine M Tangen, Dr. PH, Phyllis Goodman, MS 25) The selenium and vitamin E cancer prevention trial Eric A Klein, MD, Catherine M Tangen, Dr. PH 26) PLCO: A randomized controlled screening trial for prostate, lung, colorectal and ovarian cancer Amanda Black, PhD, E David Crawford, MD, Robert L Grubb,